VEGFA and wet macular degeneration: The safety of gene editing therapy for wet AMD will probably be further enhanced by using an LNP‐delivered Nme2Cas9 gene editing system that could specifically target retinal cells and transiently express gene editors to disrupt Vegfa gene expression.